Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM3 | P20309 | 4/20 | 0.65 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.65 |
| ▸ | ADRB2 | P07550 | 2/20 | 0.65 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.65 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.65 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.65 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.65 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.65 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.65 |
| ▸ | DRD2 | P14416 | 1/20 | 0.65 |
| ▸ | KCNE1 | P15382 | 1/20 | 0.65 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.65 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.65 |
| ▸ | HRH2 | P25021 | 1/20 | 0.65 |
| ▸ | HTR2A | P28223 | 1/20 | 0.65 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.65 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.65 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.65 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.65 |
| ▸ | HTR2B | P41595 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3946774 | 1.00 | CHRM3 (0.65) | CHRM3KCNH2ADRB2CHRM2CHRM4 | |
| SCHEMBL14033350 | 0.84 | HRH1 (0.46) | CHRM3KCNH2ADRB2CHRM2CHRM4 | |
| SCHEMBL9361492 | 0.82 | CHRM3 (0.69) | CHRM3KCNH2ADRB2CHRM2CHRM4 | |
| SCHEMBL9361499 | 0.82 | CHRM3 (0.69) | CHRM3KCNH2ADRB2CHRM2CHRM4 | |
| SCHEMBL14114512 | 0.82 | KCNH2 (0.43) | CHRM3KCNH2ADRB2CHRM2CHRM4 | |
| SCHEMBL8639889 | 0.81 | CHRM3 (0.63) | CHRM3KCNH2ADRB2CHRM2CHRM4 | |
| SCHEMBL8639887 | 0.81 | CHRM3 (0.63) | CHRM3KCNH2ADRB2CHRM2CHRM4 | |
| SCHEMBL9357002 | 0.81 | CHRM3 (0.68) | CHRM3KCNH2ADRB2CHRM2CHRM4 | |
| SCHEMBL9361555 | 0.81 | KCNH2 (0.71) | CHRM3KCNH2ADRB2CHRM2CHRM4 | |
| SCHEMBL9356996 | 0.81 | CHRM3 (0.68) | CHRM3KCNH2ADRB2CHRM2CHRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8058454-B2 | Method for preparing 1,3-disubstituted pyrrolidine compounds | MEDICHEM, S.A. (ES) | 2011-11-15 | — | — | US | disclosed |
| US-20090306406-A1 | METHOD FOR PREPARING 1,3-DISUBSTITUTED PYRROLIDINE COMPOUNDS | MEDICHEM ,S.A. (ES) | 2009-12-10 | — | — | US | disclosed |
| EP-2109601-A2 | PREPARATION OF DARIFENACIN AND ITS SALTS | Dr. Reddy's Laboratories Ltd. (IN) | 2009-10-21 | — | — | EP | disclosed |
| WO-2009125426-A2 | NOVEL PROCESS FOR THE PREPARATION OF (3SM-[2-(2 J-DIHYDRO-5- BENZOFURANYLϊETHYL]-α.α -DIPHENYL-3-PYRROLIDINEACETAMIDE HYDROBROMIDE | NEULAND LABORATORIES LTD (IN) | 2009-10-15 | — | — | WO | disclosed |
| US-20080269504-A1 | Pure darifenacin hydrobromide substantially free of oxidized darifenacin and salts thereof and processes for the preparation thereof | TEVA PHARMACEUTICAL FINE CHEMICALS S.R.I. | 2008-10-30 | — | — | US | disclosed |
| US-20080269503-A1 | Processes for preparing darifenacin hydrobromide | TEVA PHARMACEUTICALS USA, INC. FOR BARBADOS | 2008-10-30 | — | — | US | disclosed |
| US-20080269503-A1 | Processes for preparing darifenacin hydrobromide | TEVA PHARMACEUTICALS USA, INC. FOR BARBADOS | 2008-10-30 | — | — | US | disclosed |
| US-7442806-B2 | Processes for preparing darifenacin hydrobromide | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2008-10-28 | — | — | US | disclosed |
| US-7442806-B2 | Processes for preparing darifenacin hydrobromide | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2008-10-28 | — | — | US | disclosed |
| US-20080221338-A1 | Processes for preparing darifenacin hydrobromide | TEVA PHARMACEUTICALS U.S.A. INC. FOR BARBADOS | 2008-09-11 | — | — | US | disclosed |
| WO-2008029257-A2 | IMPROVED METHOD FOR PREPARING 1,3-DISUBSTITUTED PYRROLIDINE COMPOUNDS | MEDICHEM, S.A. (US) | 2008-03-13 | — | — | WO | disclosed |
| US-20070197631-A1 | Processes for preparing darifenacin hydrobromide | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2007-08-23 | — | — | US | disclosed |
| US-20070197631-A1 | Processes for preparing darifenacin hydrobromide | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2007-08-23 | — | — | US | disclosed |
| US-20070197630-A1 | Pure darifenacin hydrobromide substantially free of oxidized darifenacin and salts thereof and processes for the preparation thereof | TEVA PHARMACEUTICAL FINE CHEMICALS S.R.L. (IT) | 2007-08-23 | — | — | US | disclosed |
| US-20070197630-A1 | Pure darifenacin hydrobromide substantially free of oxidized darifenacin and salts thereof and processes for the preparation thereof | TEVA PHARMACEUTICAL FINE CHEMICALS S.R.L. (IT) | 2007-08-23 | — | — | US | disclosed |
| WO-2007076159-A2 | PURE DARIFENACIN HYDROBROMIDE SUBSTANTIALLY FREE OF OXIDIZED DARIFENACIN AND SALTS THEREOF AND PROCESSES FOR THE PREPARATION THEREOF | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2007-07-05 | — | — | WO | disclosed |
| EP-0388054-B1 | Pyrrolidine derivatives | PFIZER LTD (GB) | 1993-11-03 | — | — | EP | disclosed |
| US-5233053-A | Pyrrolidine derivatives | PFIZER INC. (US) | 1993-08-03 | — | — | US | disclosed |
| US-5096890-A | PYRROLIDINE DERIVATIVES | PFIZER INC. (US) | 1992-03-17 | — | — | US | disclosed |
| EP-0388054-A1 | Pyrrolidine derivatives | Pfizer Limited (GB) | 1990-09-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080269504-A1 | Pure darifenacin hydrobromide substantially free of oxidized darifenacin and salts thereof and processes for the preparation thereof | OPRL1, OPRK1, OPRD1 | CHRM3 87/4885KCNH2 1258/4885ADRB2 14/4885 |
| US-20080221338-A1 | Processes for preparing darifenacin hydrobromide | OPRL1, AVPR2, AVPR1B | CHRM3 69/4885KCNH2 1949/4885ADRB2 15/4885 |
| US-20070197630-A1 | Pure darifenacin hydrobromide substantially free of oxidized darifenacin and salts thereof and processes for the preparation thereof | OPRL1, OPRK1, OPRD1 | CHRM3 87/4885KCNH2 1258/4885ADRB2 14/4885 |
| US-20080269503-A1 | Processes for preparing darifenacin hydrobromide | OPRL1, AVPR2, AVPR1B | CHRM3 69/4885KCNH2 1949/4885ADRB2 15/4885 |
| US-20070197631-A1 | Processes for preparing darifenacin hydrobromide | OPRL1, AVPR2, AVPR1B | CHRM3 69/4885KCNH2 1949/4885ADRB2 15/4885 |
| US-20090306406-A1 | METHOD FOR PREPARING 1,3-DISUBSTITUTED PYRROLIDINE COMPOUNDS | OPRL1, OPRK1, OPRD1 | CHRM3 108/4885KCNH2 2108/4885ADRB2 24/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.